Update shared on04 Sep 2025
As there were no material changes in Solventum’s revenue growth or net profit margin forecasts, the consensus analyst price target remains unchanged at $86.71.
What's in the News
- Solventum completed the $4 billion divestiture of its Purification & Filtration business to Thermo Fisher, using most of the $3.4 billion net proceeds to reduce debt and strengthen the balance sheet while raising FY25 organic sales growth, adjusted EPS, free cash flow, and operating margin guidance.
- The company completed a follow-on equity offering, raising $648.12 million via the sale of 8.8 million shares at $73.65 per share; key shareholders are under a 90-day lock-up agreement post-offering.
- Solventum was removed from both the Russell 1000 Defensive and Russell 1000 Value-Defensive Indexes.
- The company launched the Attest Super Rapid VH2O2 Clear Challenge Pack, the first FDA-cleared all-in-one test pack for routine sterilization monitoring across multiple sterilizer brands and cycle types.
- Solventum raised its full-year 2025 guidance for organic sales growth to 2.0–3.0% (or 2.5–3.5% excluding SKU exits) from a previous range of 1.5–2.5%.
Valuation Changes
Summary of Valuation Changes for Solventum
- The Consensus Analyst Price Target remained effectively unchanged, at $86.71.
- The Consensus Revenue Growth forecasts for Solventum remained effectively unchanged, at 1.0% per annum.
- The Net Profit Margin for Solventum remained effectively unchanged, at 12.53%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.